INVIVO-0084, formerly known as Mutant IDH1 inhibitor, is a potent mutant IDH1 R132H inhibitor. INVIVO-0084 has CAS#1429180-08-4. INVIVO-0084 has no formal name. For the convenience of communication, we temporally name it as INVIVO-0084. The last 4 digits of its CAS number was used for name. INVIVO-0084 was reported in patent literature WO 2017213910 (Eli Lilly and Company) and WO 2013046136 (Novartis). References: Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305. doi: 10.1021/acsmedchemlett.7b00421. eCollection 2018 Apr 12. PubMed PMID: 29670690; PubMed Central PMCID: PMC5900343.

纯度：≥98%

CAS：1429180-08-4